Etanercept Biosimilar GP2015 Has Equivalent Efficacy and Safety to Etanercept Originator in Patients with Moderate to Severe Rheumatoid Arthritis: The Phase 3 Equira Study

被引：0
|
作者：
Kavanaugh, Arthur [1 ]
Allanore, Yannick [2 ]
Kucharz, Eugeniusz J. [3 ]
Babic, Goran [4 ]
机构：
[1] Univ Calif San Diego, Med, La Jolla, CA 92093 USA
[2] Paris Descartes Univ, Cochin Hosp, Dept Rheumatol, Paris, France
[3] Med Univ Silesia, Dept Internal Med & Rheumatol, Katowice, Poland
[4] Sandoz Co, Clin Dev, Biopharmaceut, Hexal AG, Holzkirchen, Germany
来源：
ARTHRITIS & RHEUMATOLOGY | 2017年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2797
引用
收藏
页数：2
相关论文
共 50 条
  • [41] A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis
    Lebwohl, Mark G.
    Kircik, Leon
    Duffin, Kristina Callis
    Pariser, David
    Hooper, Michele
    Wenkert, Deborah
    Thompson, Elizabeth H. Z.
    Yang, Jun
    Kricorian, Greg
    Koo, John
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 69 (03) : 385 - 392
  • [42] A Phase III, Randomized, Double-Blind Clinical Study Comparing SB4, an Etanercept Biosimilar, with Etanercept Reference Product (Enbrel®) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (52-week Results)
    Vencovsky, Jiri
    Sylwestrzak, Anna
    Leszczynski, Piotr
    Porawska, Wieslawa
    Baranauskaite, Asta
    Tseluyko, Vira
    Zhdan, Vyacheslav
    Stasiuk, Barbara
    Milasiene, Roma
    Barrera Rodriguez, Aaron Alejandro
    Cheong, Soo Yeon
    Ghil, Jeehoon
    Emery, Paul
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [43] A PHASE III RANDOMISED, DOUBLE-BLIND CLINICAL STUDY COMPARING SB4, AN ETANERCEPT BIOSIMILAR, WITH ETANERCEPT REFERENCE PRODUCT (ENBREL®) IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS DESPITE METHOTREXATE THERAPY (24-WEEK RESULTS)
    Vencovsky, J.
    Sylwestrzak, A.
    Leszczynski, P.
    Porawska, W.
    Baranauskaite, A.
    Tseluyko, V.
    Zhdan, V.
    Stasiuk, B.
    Milasiene, R.
    Rodriguez, A. A. Barrera
    Cheong, S. Y.
    Ghil, J.
    Emery, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 467 - 468
  • [44] Multicenter, Evaluator-blinded, Randomized, Non-inferiority Study, to Assess the Efficacy, Safety and Immunogenicity of Etanercept Biosimilar (EtaBS) vs. Reference Etanercept (EtaRef) in Combination with Methotrexate for the Treatment of Patients with Rheumatoid Arthritis
    Strusberg, Ingrid
    Siri, Daniel
    Correa, Maria
    Scarafia, Santiago
    Pardo Hidalgo, Rodolfo
    Spindler, Alberto
    Tate, Patricio
    Venarotti, Horacio
    Velasco Zamora, Jorge
    Citera, Gustavo
    Mysler, Eduardo
    Klimovsky, Ezequiel
    Federico, Andrea
    Eizikovits, Gabriela
    Cordeiro, Lucas
    Lago, Nestor
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [45] Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study
    Cohen, Stanley
    Genovese, Mark C.
    Choy, Ernest
    Perez-Ruiz, Fernando
    Matsumoto, Alan
    Pavelka, Karel
    Pablos, Jose L.
    Rizzo, Warren
    Hrycaj, Pawel
    Zhang, Nan
    Shergy, William
    Kaur, Primal
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (10) : 1679 - 1687
  • [46] Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis
    Klareskog, L.
    Gaubitz, M.
    Rodriguez-Valverde, V.
    Malaise, M.
    Dougados, M.
    Wajdula, J.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2011, 29 (02) : 238 - 247
  • [47] SIMILAR EFFICACY AND SAFETY OF BIOSIMILAR CANDIDATE BI 695501 AND ADALIMUMAB ORIGINATOR REFERENCE PRODUCT IN PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS: 24 WEEK RESULTS FROM A PHASE III CLINICAL STUDY (VOLTAIRE®-RA)
    Cohen, S.
    Alonso-Ruiz, A.
    Klimiuk, P. A.
    Lee, E.
    Peter, N.
    Sonderegger, I.
    Assudani, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 553 - 553
  • [48] A Randomized, Double-Blind, Phase 3 Equivalence Trial Comparing the Etanercept Biosimilar, HD203, with Etanercept (Enbrel®), in Combination with Methotrexate (MTX) in Patients with Rheumatoid Arthritis (RA).
    Bae, Sang-Cheol
    Kim, Jinseok
    Choe, Jung-Yoon
    Park, Won
    Lee, So-Ra
    Ahn, Yongho
    Seo, Yunjeong
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S1234 - S1234
  • [49] Effectiveness After Transition to SB4 (Brenzys, Etanercept Biosimilar) versus Continuation of Etanercept (ETN) Originator (Enbrel) Among Rheumatoid Arthritis (RA) Patients in Low Disease Activity: A Prospective Multinational Multicenter Observational Study
    Pope, Janet
    Hall, Stephen
    Bombardier, Claire
    Keystone, Edward C.
    Haraoui, Boulos
    Jones, Graeme
    Naik, Latha
    Wu, Wei David
    Ramey, Dena
    Infante, Ricardo
    Etzel, Carol
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [50] Efficacy and safety of HLX01 in patients with moderate-to-severe rheumatoid arthritis despite methotrexate therapy: a phase 3 study
    Xiaofeng Zeng
    Ju Liu
    Xiumei Liu
    Lijun Wu
    Yi Liu
    Xiangping Liao
    Huaxiang Liu
    Jiankang Hu
    Xin Lu
    Linjie Chen
    Jian Xu
    Zhenyu Jiang
    Fu-ai Lu
    Huaxiang Wu
    Ying Li
    Qingyu Wang
    Jun Zhu
    Arthritis Research & Therapy, 24
12345